Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Zacks Investment Research9/17/2026Positive
KNSA
Kiniksa Pharmaceuticals LtdNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$5.86B
P/E Ratio
75.84
EPS
$0.99
Beta
0.09
52W High
$82.94
52W Low
$35.20
50-Day MA
$75.48
200-Day MA
$55.19
Dividend Yield
—
Profit Margin
9.59%
Forward P/E
59.52
PEG Ratio
—
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | $840.85M |
| Gross Profit (TTM) | $458.30M |
| EBITDA | $102.04M |
| Operating Margin | 11.20% |
| Return on Equity | 14.00% |
| Return on Assets | 8.05% |
| Revenue/Share (TTM) | $11.03 |
| Book Value | $8.39 |
| Price-to-Book | 9.07 |
| Price-to-Sales (TTM) | 6.97 |
| EV/Revenue | 6.44 |
| EV/EBITDA | 53.05 |
| Quarterly Earnings Growth (YoY) | 30.40% |
| Quarterly Revenue Growth (YoY) | 55.40% |
| Shares Outstanding | $48.29M |
| Float | $39.86M |
| % Insiders | 3.51% |
| % Institutions | 100.91% |
Historical Volatility
HV 10-Day
31.05%
HV 20-Day
28.63%
HV 30-Day
28.54%
HV 60-Day
58.38%
HV Rank
12.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($98.00 target)
1
Strong Buy7
BuyLatest News
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
GlobeNewsWire9/4/2026Neutral
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.
GlobeNewsWire8/7/2026Neutral
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Zacks Investment Research8/3/2026Positive
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research7/30/2026Positive
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment.
MarketBeat7/28/2026Positive
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year ago.
Zacks Investment Research7/28/2026Positive
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients – – Conference call and webcast scheduled for 8:30 am ET today –
GlobeNewsWire7/28/2026Neutral
5 Stocks With Recent Price Strength Despite Recent Market Volatility
Despite a volatile market, AOUT, CMPR, NESR, CTO and KNSA are five stocks showing recent price strength.
Zacks Investment Research7/23/2026Negative
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research7/22/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KNSA and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026